Cargando…
Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial
SIMPLE SUMMARY: Patients with medulloblastoma receive treatment according to a risk stratification, which is a combination of clinical and biological factors. To date there have been a limited number of trials for high-risk disease in children older than 3 years, with a wide range of treatment philo...
Autores principales: | Bailey, Simon, André, Nicolas, Gandola, Lorenza, Massimino, Maura, Rutkowski, Stefan, Clifford, Steven C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773789/ https://www.ncbi.nlm.nih.gov/pubmed/35053536 http://dx.doi.org/10.3390/cancers14020374 |
Ejemplares similares
-
QOL-17. BIOLOGICAL CORRELATES OF QUALITY OF SURVIVAL AND NEUROCOGNITIVE OUTCOMES IN MEDULLOBLASTOMA; A META-ANALYSIS OF THE SIOP-UKCCSG-PNET3 AND HIT-SIOP-PNET4 TRIALS
por: Chevignard, Mathilde, et al.
Publicado: (2020) -
MEDB-40. RUNNING FOR INCLUSION IN SIOPE PNET5 MB
por: Massimino, Maura, et al.
Publicado: (2022) -
SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma
por: Mynarek, Martin, et al.
Publicado: (2021) -
Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study
por: Sabel, Magnus, et al.
Publicado: (2016) -
Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma: First experiences of the German radiotherapy quality control panel in the SIOP PNET5 MB trial
por: Dietzsch, Stefan, et al.
Publicado: (2020)